Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 1, 2014, Pages 12-19

  Inoue, Katsuhisa ^a   Yuasa, Hiroaki ^b  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

ABC transporters; Genetic polymorphisms; Interpatient variability; Methotrexate; PCFT; Pharmacodynamics; Pharmacokinetics; RFC1

Indexed keywords

ABC TRANSPORTER; CELECOXIB; ETORICOXIB; FOLATE RECEPTOR; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NAPROXEN; ORGANIC ANION TRANSPORTER 3; PROTON COUPLED FOLATE TRANSPORTER; PYRIMETHAMINE; REDUCED FOLATE CARRIER; SALAZOSULFAPYRIDINE;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; MICHAELIS CONSTANT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; FOLATE RECEPTOR 2; HUMANS; METHOTREXATE; ORGANIC ANION TRANSPORTERS; TISSUE DISTRIBUTION;

EID: 84898486297     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RV-119     Document Type: Review

References (100)

1. Chattopadhyay, S., Moran, R. G. and Goldman, I. D.: Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol. Cancer Ther., 6: 404-417 (2007).
2. Cronstein, B. N.: Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev., 57: 163-172 (2005).
3. Jacobs, J. W. G.: Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford), 51 Suppl 4: iv3-iv8 (2012).
4. Singh, J. A., Furst, D. E., Bharat, A., Curtis, J. R., Kavanaugh, A. F., Kremer, J. M., Moreland, L. W., O'Dell, J., Winthrop, K. L., et al.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken), 64: 625-639 (2012).
5. Yuasa, H., Inoue, K. and Hayashi, Y.: Molecular and functional characteristics of proton-coupled folate transporter. J. Pharm. Sci., 98: 1608-1616 (2009).
6. Braun, J., Kästner, P., Flaxenberg, P., Währisch, J., Hanke, P., Demary, W., von Hinüber, U., Rockwitz, K., Heitz, W., et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum., 58: 73-81 (2008).
7. Visser, K. and van der Heijde, D.: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis., 68: 1094-1099 (2009).
8. Hamilton, R. A. and Kremer, J. M.: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br. J. Rheumatol., 36: 86-90 (1997).
9. Hoekstra, M., Haagsma, C., Neef, C., Proost, J., Knuif, A. and van de Laar, M.: Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J. Rheumatol., 31: 645-648 (2004).
10. Oguey, D., Kölliker, F., Gerber, N. J. and Reichen, J.: Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum., 35: 611-614 (1992).
11. Seideman, P., Beck, O., Eksborg, S. and Wennberg, M.: The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br. J. Clin. Pharmacol., 35: 409-412 (1993).
12. Rochas, M. A., Tufenkji, A. E., Levillain, P. and Houin, G.: Protein binding of methotrexate to human albumin and serum. A first derivative spectroscopic analysis. Arzneimittelforschung, 41: 1286-1288 (1991).
13. Paxton, J. W.: Protein binding of methotrexate in sera from normal human beings: effect of drug concentration, pH, temperature, and storage. J. Pharmacol. Methods, 5: 203-213 (1981).
14. Bannwarth, B., Péhourcq, F., Schaeverbeke, T. and Dehais, J.: Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet., 30: 194-210 (1996).
15. Herman, R. A., Veng-Pedersen, P., Hoffman, J., Koehnke, R. and Furst, D. E.: Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J. Pharm. Sci., 78: 165-171 (1989).
16. Chabner, B. A., Allegra, C. J., Curt, G. A., Clendeninn, N. J., Baram, J., Koizumi, S., Drake, J. C. and Jolivet, J.: Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest., 76: 907-912 (1985).
17. Chládek, J., Grim, J., Martínková, J., Simková, M., Vanìèková, J., Koudelková, V. and Noièková, M.: Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br. J. Clin. Pharmacol., 54: 147-156 (2002).
18. Nuernberg, B., Koehnke, R., Solsky, M., Hoffman, J. and Furst, D. E.: Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum., 33: 898-902 (1990).
19. Allegra, C. J., Drake, J. C., Jolivet, J. and Chabner, B. A.: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Natl. Acad. Sci. USA, 82: 4881-4885 (1985).
20. Funk, R. S., van Haandel, L., Becker, M. L. and Leeder, J. S.: Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line. J. Pharmacol. Exp. Ther., 347: 154-163 (2013).
21. Haskó, G., Linden, J., Cronstein, B. and Pacher, P.: Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov., 7: 759-770 (2008).
22. Cejka, D., Hayer, S., Niederreiter, B., Sieghart, W., Fuereder, T., Zwerina, J. and Schett, G.: Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum., 62: 2294-2302 (2010).
23. Racanelli, A. C., Rothbart, S. B., Heyer, C. L. and Moran, R. G.: Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res., 69: 5467-5474 (2009).
24. Lafforgue, P., Monjanel-Mouterde, S., Durand, A., Catalin, J. and Acquaviva, P. C.: Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J. Rheumatol., 22: 844-849 (1995).
25. Danila, M. I., Hughes, L. B., Brown, E. E., Morgan, S. L., Baggott, J. E., Arnett, D. K. and Bridges, S. L.: Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis? Curr. Rheumatol. Rep., 12: 342-347 (2010).
26. Da Costa, M. and Iqbal, M. P.: The transport and accumulation of methotrexate in human erythrocytes. Cancer, 48: 2427-2432 (1981).
27. DeGorter, M. K., Xia, C. Q., Yang, J. J. and Kim, R. B.: Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol., 52: 249-273 (2012).
28. Sirotnak, F. M. and Tolner, B.: Carrier-mediated membrane transport of folates in mammalian cells. Annu. Rev. Nutr., 19: 91-122 (1999).
29. Desmoulin, S. K., Hou, Z., Gangjee, A. and Matherly, L. H.: The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol. Ther., 13: 1355-1373 (2012).
30. Shayeghi, M., Latunde-Dada, G. O., Oakhill, J. S., Laftah, A. H., Takeuchi, K., Halliday, N., Khan, Y., Warley, A., McCann, F. E., et al.: Identification of an intestinal heme transporter. Cell, 122: 789-801 (2005).
31. Qiu, A., Jansen, M., Sakaris, A., Min, S. H., Chattopadhyay, S., Tsai, E., Sandoval, C., Zhao, R., Akabas, M. H., et al.: Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell, 127: 917-928 (2006).
32. +-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp. Physiol., 92: 603-619 (2007).
33. Inoue, K., Nakai, Y., Ueda, S., Kamigaso, S., Ohta, K., Hatakeyama, M., Hayashi, Y., Otagiri, M. and Yuasa, H.: Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am. J. Physiol. Gastrointest. Liver Physiol., 294: G660-G668 (2008).
34. Nakai, Y., Inoue, K., Abe, N., Hatakeyama, M., Ohta, K., Otagiri, M., Hayashi, Y. and Yuasa, H.: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J. Pharmacol. Exp. Ther., 322: 469-476 (2007).
35. Diop-Bove, N. K., Wu, J., Zhao, R., Locker, J. and Goldman, I. D.: Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line. Mol. Cancer Ther., 8: 2424-2431 (2009).
36. Furumiya, M., Inoue, K., Ohta, K., Hayashi, Y. and Yuasa, H.: Transcriptional regulation of PCFT by KLF4, HNF4α, CDX2 and C/EBPα: implication in its site-speci fic expression in the small intestine. Biochem. Biophys. Res. Commun., 431: 158-163 (2013).
37. Eloranta, J. J., Zaïr, Z. M., Hiller, C., Häusler, S., Stieger, B. and Kullak-Ublick, G. A.: Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter. Mol. Pharmacol., 76: 1062-1071 (2009).
38. Urquhart, B. L., Gregor, J. C., Chande, N., Knauer, M. J., Tirona, R. G. and Kim, R. B.: The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. Am. J. Physiol. Gastrointest. Liver Physiol., 298: G248-G254 (2010).
39. Dixon, K. H., Lanpher, B. C., Chiu, J., Kelley, K. and Cowan, K. H.: A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J. Biol. Chem., 269: 17-20 (1994).
40. Zhao, R., Russell, R. G., Wang, Y., Liu, L., Gao, F., Kneitz, B., Edelmann, W. and Goldman, I. D.: Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J. Biol. Chem., 276: 10224-10228 (2001).
41. Zhao, R., Gao, F. and Goldman, I. D.: Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am. J. Physiol. Cell Physiol., 282: C1512-C1517 (2002).
42. Zhao, R. and Goldman, I. D.: Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol. Aspects Med., 34: 373-385 (2013).
43. Whetstine, J. R., Flatley, R. M. and Matherly, L. H.: The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem. J., 367: 629-640 (2002).
44. Wang, Y., Zhao, R., Russell, R. G. and Goldman, I. D.: Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim. Biophys. Acta, 1513: 49-54 (2001).
45. Min, S. H., Oh, S. Y., Karp, G. I., Poncz, M., Zhao, R. and Goldman, I. D.: The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption. J. Pediatr., 153: 435-437 (2008).
46. Stamp, L. K., Hazlett, J., Highton, J. and Hessian, P. A.: Expression of methotrexate transporters and metabolizing enzymes in rheumatoid synovial tissue. J. Rheumatol., 40: 1519-1522 (2013).
47. Chango, A., Emery-Fillon, N., de Courcy, G. P., Lambert, D., Pfister, M., Rosenblatt, D. S. and Nicolas, J. P.: A polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol. Genet. Metab., 70: 310-315 (2000).
48. Whetstine, J. R., Gifford, A. J., Witt, T., Liu, X. Y., Flatley, R. M., Norris, M., Haber, M., Taub, J. W., Ravindranath, Y., et al.: Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin. Cancer Res., 7: 3416-3422 (2001).
49. Laverdière, C., Chiasson, S., Costea, I., Moghrabi, A. and Krajinovic, M.: Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood, 100: 3832-3834 (2002).
50. Dervieux, T., Kremer, J., Lein, D. O., Capps, R., Barham, R., Meyer, G., Smith, K., Caldwell, J. and Furst, D. E.: Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 14: 733-739 (2004).
51. Ando, Y., Shimada, H., Matsumoto, N., Hirota, T., Oribe, M., Otsuka, E., Ishii, K., Morimoto, T., Ohashi, K., et al.: Role of Methotrexate Polyglutamation and Reduced Folate Carrier 1 (RFC1) Gene Polymorphisms in Clinical Assessment Indexes. Drug Metab. Pharmacokinet., 28: 442-445 (2013).
52. Drozdzik, M., Rudas, T., Pawlik, A., Gornik, W., Kurzawski, M. and Herczynska, M.: Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J., 7: 404-407 (2007).
53. Hayashi, H., Tazoe, Y., Tsuboi, S., Horino, M., Morishita, M., Arai, T., Ohshima, M., Matsuyama, T., Kosuge, K., et al.: A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinet., 28: 164-168 (2013).
54. Morin, I., Devlin, A. M., Leclerc, D., Sabbaghian, N., Halsted, C. H., Finnell, R. and Rozen, R.: Evaluation of genetic variants in the reduced folate carrier and in glutamate carboxypeptidase II for spina bifida risk. Mol. Genet. Metab., 79: 197-200 (2003).
55. James, H. M., Gillis, D., Hissaria, P., Lester, S., Somogyi, A. A., Cleland, L. G. and Proudman, S. M.: Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J. Rheumatol., 35: 562-571 (2008).
56. Kato, T., Hamada, A., Mori, S. and Saito, H.: Genetic polymorphisms in metabolic and cellular transport pathway of methotrexate impact clinical outcome of methotrexate monotherapy in Japanese patients with rheumatoid arthritis. Drug Metab. Pharmacokinet., 27: 192-199 (2012).
57. Wessels, J. A. M., de Vries-Bouwstra, J. K., Heijmans, B. T., Slagboom, P. E., Goekoop-Ruiterman, Y. P. M., Allaart, C. F., Kerstens, P. J. S. M., van Zeben, D., Breedveld, F. C., et al.: Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum., 54: 1087-1095 (2006).
58. Antony, A. C.: Folate receptors. Annu. Rev. Nutr., 16: 501-521 (1996).
59. Reddy, J. A., Haneline, L. S., Srour, E. F., Antony, A. C., Clapp, D. W. and Low, P. S.: Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood, 93: 3940-3948 (1999).
60. Nakashima-Matsushita, N., Homma, T., Yu, S., Matsuda, T., Sunahara, N., Nakamura, T., Tsukano, M., Ratnam, M. and Matsuyama, T.: Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum., 42: 1609-1616 (1999).
61. Van der Heijden, J. W., Oerlemans, R., Dijkmans, B. A. C., Qi, H., van der Laken, C. J., Lems, W. F., Jackman, A. L., Kraan, M. C., Tak, P. P., et al.: Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum., 60: 12-21 (2009).
62. Tsuneyoshi, Y., Tanaka, M., Nagai, T., Sunahara, N., Matsuda, T., Sonoda, T., Ijiri, K., Komiya, S. and Matsuyama, T.: Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. Scand. J. Rheumatol., 41: 132-140 (2012).
63. Feng, Y., Shen, J., Streaker, E. D., Lockwood, M., Zhu, Z., Low, P. S. and Dimitrov, D. S.: A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res. Ther., 13: R59 (2011).
64. Burckhardt, G.: Drug transport by Organic Anion Transporters (OATs). Pharmacol. Ther., 136: 106-130 (2012).
65. Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Hosoyamada, M., Cha, S. H., Sekine, T. and Endou, H.: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther., 302: 666-671 (2002).
66. Uwai, Y., Taniguchi, R., Motohashi, H., Saito, H., Okuda, M. and Inui, K.: Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab. Pharmacokinet., 19: 369-374 (2004).
67. Nishizato, Y., Ieiri, I., Suzuki, H., Kimura, M., Kawabata, K., Hirota, T., Takane, H., Irie, S., Kusuhara, H., et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther., 73: 554-565 (2003).
68. Ogasawara, K., Terada, T., Motohashi, H., Asaka, J.-I., Aoki, M., Katsura, T., Kamba, T., Ogawa, O. and Inui, K.-I.: Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. J. Hum. Genet., 53: 607-614 (2008).
69. Nozaki, Y., Kusuhara, H., Endou, H. and Sugiyama, Y.: Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther., 309: 226-234 (2004).
70. VanWert, A. L. and Sweet, D. H.: Impaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folates. Pharm. Res., 25: 453-462 (2008).
71. Frenia, M. L. and Long, K. S.: Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother., 26: 234-237 (1992).
72. Thyss, A., Milano, G., Kubar, J., Namer, M. and Schneider, M.: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 1: 256-258 (1986).
73. Dupuis, L. L., Koren, G., Shore, A., Silverman, E. D. and Laxer, R. M.: Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis. J. Rheumatol., 17: 1469-1473 (1990).
74. Vakily, M., Amer, F., Kukulka, M. J. and Andhivarothai, N.: Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis. J. Clin. Pharmacol., 45: 1179-1186 (2005).
75. Karim, A., Tolbert, D. S., Hunt, T. L., Hubbard, R. C., Harper, K. M. and Geis, G. S.: Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Rheumatol., 26: 2539-2543 (1999).
76. Schwartz, J. I., Agrawal, N. G. B., Wong, P. H., Miller, J., Bachmann, K., Marbury, T., Hoelscher, D., Cavanaugh, P. F. and Gottesdiener, K.: Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J. Clin. Pharmacol., 49: 1202-1209 (2009).
77. Ieiri, I.: Functional significance of genetic polymorphisms in Pglycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet., 27: 85-105 (2012).
78. Drozdzik, M., Rudas, T., Pawlik, A., Kurzawski, M., Czerny, B., Gornik, W. and Herczynska, M.: The effect of 3435C >T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol., 62: 933-937 (2006).
79. De Rotte, M. C. F. J., Bulatovic, M., Heijstek, M. W., Jansen, G., Heil, S. G., van Schaik, R. H. N., Wulffraat, N. M. and de Jonge, R.: ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J. Rheumatol., 39: 2032-2040 (2012).
80. Takatori, R., Takahashi, K. A., Tokunaga, D., Hojo, T., Fujioka, M., Asano, T., Hirata, T., Kawahito, Y., Satomi, Y., et al.: ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 24: 546-554 (2006).
81. Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V. and Gottesman, M. M.: A "silent " polymorphism in the MDR1 gene changes substrate specificity. Science, 315: 525-528 (2007).
82. Slot, A. J., Molinski, S. V. and Cole, S. P. C.: Mammalian multidrug-resistance proteins (MRPs). Essays Biochem., 50: 179-207 (2011).
83. Zeng, H., Chen, Z. S., Belinsky, M. G., Rea, P. A. and Kruh, G. D.: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res., 61: 7225-7232 (2001).
84. Kool, M., van der Linden, M., de Haas, M., Scheffer, G. L., de Vree, J. M., Smith, A. J., Jansen, G., Peters, G. J., Ponne, N., et al.: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA, 96: 6914-6919 (1999).
85. Kitamura, Y., Hirouchi, M., Kusuhara, H., Schuetz, J. D. and Sugiyama, Y.: Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3). J. Pharmacol. Exp. Ther., 327: 465-473 (2008).
86. Bakos, E., Evers, R., Sinkó, E., Váradi, A., Borst, P. and Sarkadi, B.: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol., 57: 760-768 (2000).
87. El-Sheikh, A. A. K., van den Heuvel, J. J. M. W., Koenderink, J. B. and Russel, F. G. M.: Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther., 320: 229-235 (2007).
88. Chen, Z.-S., Lee, K., Walther, S., Raftogianis, R. B., Kuwano, M., Zeng, H. and Kruh, G. D.: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res., 62: 3144-3150 (2002).
89. Wielinga, P., Hooijberg, J. H., Gunnarsdottir, S., Kathmann, I., Reid, G., Zelcer, N., van der Born, K., de Haas, M., van der Heijden, I., et al.: The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res., 65: 4425-4430 (2005).
90. Volk, E. L. and Schneider, E.: Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res., 63: 5538-5543 (2003).
91. Ranganathan, P., Culverhouse, R., Marsh, S., Mody, A., Scott-Horton, T. J., Brasington, R., Joseph, A., Reddy, V., Eisen, S., et al.: Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J. Rheumatol., 35: 572-579 (2008).
92. Yao, R., Schneider, E., Ryan, T. J. and Galivan, J.: Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc. Natl. Acad. Sci. USA, 93: 10134-10138 (1996).
93. Cheng, Q., Wu, B., Kager, L., Panetta, J. C., Zheng, J., Pui, C.-H., Relling, M. V. and Evans, W. E.: A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics, 14: 557-567 (2004).
94. Owen, S. A., Hider, S. L., Martin, P., Bruce, I. N., Barton, A. and Thomson, W.: Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J., 13: 227-234 (2013).
95. Chave, K. J., Ryan, T. J., Chmura, S. E. and Galivan, J.: Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene, 319: 167-175 (2003).
96. Panetta, J. C., Wall, A., Pui, C.-H., Relling, M. V. and Evans, W. E.: Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin. Cancer Res., 8: 2423-2429 (2002).
97. Cole, P. D., Kamen, B. A., Gorlick, R., Banerjee, D., Smith, A. K., Magill, E. and Bertino, J. R.: Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res., 61: 4599-4604 (2001).
98. Barrueco, J. R., O'Leary, D. F. and Sirotnak, F. M.: Facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Further characterization and evidence for a simple mobile carrier system with broad specificity for homo- or heteropeptides bearing a C-terminal glutamyl moiety. J. Biol. Chem., 267: 19986-19991 (1992).
99. Marshall, L. A., Rhee, M. S., Hofmann, L., Khodjakov, A. and Schneider, E.: Increased lysosomal uptake of methotrexate-polyglutamates in two methotrexate-resistant cell lines with distinct mechanisms of resistance. Biochem. Pharmacol., 71: 203-213 (2005).
100. De Beaumais, T. A. and Jacqz-Aigrain, E.: Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children. Curr. Drug Metab., 13: 822-834 (2012).